{"title":"法利西单抗与阿非利赛普治疗黄斑新生血管早期血管结构变化的OCT血管造影比较。","authors":"Shinichiro Chujo, Hisashi Matsubara, Yoko Mase, Yukiko Muramoto, Kumiko Kato, Mineo Kondo","doi":"10.2147/OPTH.S549586","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate whether Faricimab, which targets Ang-2, can reduce macular neovascularization (MNV) metrics on OCTA compared with Aflibercept in treatment-naïve nAMD.</p><p><strong>Methods: </strong>Among 34 eyes treated with Aflibercept, 12 eyes were included; among 31 eyes treated with Faricimab, 14 eyes were included. Vessel area (Va) and junction density (JD) were measured using AngioTool over a 3-month loading period.</p><p><strong>Results: </strong>In the Faricimab group, mean Va changed from 0.14 mm<sup>2</sup> at baseline to 0.15 mm<sup>2</sup> at 3 months; JD changed from 0.16 to 0.15/mm. In the Aflibercept group, Va decreased from 0.29 to 0.20 mm<sup>2</sup>, and JD changed from 0.77 to 0.83/mm. Differences in Va and JD between groups were not statistically significant.</p><p><strong>Conclusion: </strong>There were no significant structural changes in MNV with either drug over the short term. These findings suggest that vascular effects of Faricimab may require longer observation to become evident.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"3527-3533"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12476195/pdf/","citationCount":"0","resultStr":"{\"title\":\"Comparisons of Early Changes of Vascular Structure After Treatment with Faricimab and Aflibercept in Eyes with Macular Neovascularization by OCT Angiography.\",\"authors\":\"Shinichiro Chujo, Hisashi Matsubara, Yoko Mase, Yukiko Muramoto, Kumiko Kato, Mineo Kondo\",\"doi\":\"10.2147/OPTH.S549586\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To evaluate whether Faricimab, which targets Ang-2, can reduce macular neovascularization (MNV) metrics on OCTA compared with Aflibercept in treatment-naïve nAMD.</p><p><strong>Methods: </strong>Among 34 eyes treated with Aflibercept, 12 eyes were included; among 31 eyes treated with Faricimab, 14 eyes were included. Vessel area (Va) and junction density (JD) were measured using AngioTool over a 3-month loading period.</p><p><strong>Results: </strong>In the Faricimab group, mean Va changed from 0.14 mm<sup>2</sup> at baseline to 0.15 mm<sup>2</sup> at 3 months; JD changed from 0.16 to 0.15/mm. In the Aflibercept group, Va decreased from 0.29 to 0.20 mm<sup>2</sup>, and JD changed from 0.77 to 0.83/mm. Differences in Va and JD between groups were not statistically significant.</p><p><strong>Conclusion: </strong>There were no significant structural changes in MNV with either drug over the short term. These findings suggest that vascular effects of Faricimab may require longer observation to become evident.</p>\",\"PeriodicalId\":93945,\"journal\":{\"name\":\"Clinical ophthalmology (Auckland, N.Z.)\",\"volume\":\"19 \",\"pages\":\"3527-3533\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-09-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12476195/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical ophthalmology (Auckland, N.Z.)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/OPTH.S549586\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical ophthalmology (Auckland, N.Z.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/OPTH.S549586","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
Comparisons of Early Changes of Vascular Structure After Treatment with Faricimab and Aflibercept in Eyes with Macular Neovascularization by OCT Angiography.
Objective: To evaluate whether Faricimab, which targets Ang-2, can reduce macular neovascularization (MNV) metrics on OCTA compared with Aflibercept in treatment-naïve nAMD.
Methods: Among 34 eyes treated with Aflibercept, 12 eyes were included; among 31 eyes treated with Faricimab, 14 eyes were included. Vessel area (Va) and junction density (JD) were measured using AngioTool over a 3-month loading period.
Results: In the Faricimab group, mean Va changed from 0.14 mm2 at baseline to 0.15 mm2 at 3 months; JD changed from 0.16 to 0.15/mm. In the Aflibercept group, Va decreased from 0.29 to 0.20 mm2, and JD changed from 0.77 to 0.83/mm. Differences in Va and JD between groups were not statistically significant.
Conclusion: There were no significant structural changes in MNV with either drug over the short term. These findings suggest that vascular effects of Faricimab may require longer observation to become evident.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
